A subgroup of patients with drug-resistant epilepsy have seizure clusters, which are a part of the continuum of seizure emergencies that includes prolonged episodes and status epilepticus. When the patient or caregiver can identify the beginning of a cluster, the condition is amenable to certain treatments, an approach known as rescue therapy. Intravenous drug administration offers the fastest onset of action, but this route is usually not an option because most seizure clusters occur outside of a medical facility. Alternate routes of administration have been used or are proposed including rectal, buccal, intrapulmonary, subcutaneous, intramuscular, and intranasal. The objective of this narrative review is to describe the (1) anatomical, physiologic, and drug physicochemical properties that need to be considered when developing therapies for seizure emergencies and (2) products currently in development. New therapies must consider parameters of Fick's law such as absorptive surface area, blood flow, membrane thickness, and lipid solubility, because these factors affect both rate and extend of absorption. For example, the lung has a 50 000-fold greater absorptive surface area than that associated with a subcutaneous injection. Lipid solubility is a physicochemical property that influences the absorption rate of small molecule drugs. Among drugs currently used or under development for rescue therapy, allopregnanolone has the greatest lipid solubility at physiologic pH, followed by propofol, midazolam, diazepam, lorazepam, alprazolam, and brivaracetam. However, greater lipid solubility correlates with lower water solubility, complicating formulation of rescue therapies. One approach to overcoming poor aqueous solubility involves the use of a watersoluble prodrug coadministered with a converting enzyme, which is being explored for the intranasal delivery of diazepam. With advances in seizure prediction technology and the development of drug delivery systems that provide rapid onset of effect, rescue therapies may prevent the occurrence of seizures, thus greatly improving the management of epilepsy.
| INTRODUCTION
A subgroup of patients with drug-resistant epilepsy have seizure clusters, also known as acute repetitive seizures. 1 This condition is a subset of the continuum of seizure emergencies that includes prolonged seizures and status epilepticus (SE). When the patient or caregiver can identify the onset of a cluster, the condition is amenable to treatment, an approach known as rescue therapy. 2 The objective of such therapy, namely rapid termination of the episode, is best accomplished by intravenous (IV) administration of an appropriate drug, typically a benzodiazepine (BZD). 3 However, most seizure clusters occur outside of the hospital, which precludes or delays intravenous administration unless performed by emergency medical personnel. Therefore, there is considerable interest in out-of-hospital rescue therapies given by alternate routes of administration.
Characteristics of an ideal rescue therapy for treatment of seizure clusters include the following: a broad spectrum of activity, intermediate duration of action, rapid (within minutes) cessation of seizures, ease of use, safety and minimal discomfort, low inter-and intrapatient variability, adult and pediatric doses/delivery systems, and long shelf life. 4 In most situations, oral administration is not a viable treatment option due to slow transit time, choking hazard, or inability of the patient to swallow. As alternatives to intravenous administration, rectal diazepam (DZP) and buccal midazolam (MDZ) 3 are now used as rescue therapies, whereas other approaches as listed in Table 1 are under development. In developing a rescue therapy, anatomic and physiologic factors associated with a route of administration must be considered along with physicochemical properties of the drug.
| ANATOMIC AND PHYSIOLOGIC

FACTORS AFFECTING DRUG ABSORPTION
When considering rescue therapy administered by routes other than intravenous administration, the rate and extent of drug absorption from a tissue is a paramount concern. These processes are largely governed by Fick's law:
Anatomic/physiologic factors of the tissues involved in alternate routes of administration include the absorptive surface area, diffusion coefficient, blood flow, and membrane thickness. As shown in Table 2 , there are substantial differences in the surface areas and perfusion of tissues exposed to drug at the administration site. Blood flowing through the capillary beds in these tissues acts as a sink, carrying drug away from the site by advection and maintaining a concentration gradient. More highly perfused tissues tend to have higher capillary densities, thereby reducing the distance in the tissue through which the drug must diffuse before reaching the blood. For example, differences in the vascularity of skeletal muscle in the arm, thigh, and buttocks can account for the different drug absorption rates observed following intramuscular (IM) injections of the same drug (rate: arm > thigh > buttocks). 5 In most cases for a given drug, the greater the absorptive surface area and blood flow, the faster drug absorption takes place. As a general rule, the rate of absorption differs by route with intrapulmonary (IP) being greater than intranasal (IN) followed by rectal, buccal, IM, and subcutaneous (SC). The lungs have the greatest absorptive surface area and a very high perfusion rate. Furthermore, the alveolar-capillary membrane is exceptionally thin (2-0.6 μm). These factors render IP delivery as an attractive route for drugs that must be absorbed quickly. The nasal epithelium is also quite thin, 40-80 μm, 18 compared to rectal and buccal epithelia, 160-190 μm and 500-800 μm, respectively. 19, 20 The porous epithelium in the olfactory region of the nasal cavity and olfactory nerve bundle offers the 
CHARACTERISTICS THAT AFFECT DRUG ABSORPTION
The partition coefficient in Fick's law reflects a drug's lipid solubility. Lipid-soluble drugs tend to partition from polar aqueous environments into the nonpolar environment of lipid membranes. Partitioning has a major influence on systemic pharmacokinetics (PK) and the drug's ability to cross the blood-brain barrier (BBB). Partition coefficient (LogP) and polar surface area are common metrics used to describe lipid solubility. 23 As shown in Table 3 , most of the drugs used or under development for rescue therapy have high LogP values and small polar surface areas, indicating high lipid solubilities. Lipophilic drugs usually have poor water solubility. However, drugs must be in solution to diffuse across biologic membranes. Formulation of lipophilic drugs typically necessitates the use of organic cosolvents such as alcohol or glycols, which can increase drug concentration in a formulation while limiting the volume required to deliver a clinically relevant dose. Organic cosolvents can also have toxic effects, particularly in sensitive tissues exposed to high cosolvent levels. 25, 26 One drug formulation used for seizure emergencies that avoids the use of cosolvents is MDZ injectable, USP, which has a pH of approximately 3 creating an open-ring, water-soluble configuration. Upon exposure to physiologic pH, the ring closes, resulting in a highly lipophilic form. 27 However, the | 209 acidic pH of the MDZ parenteral formulation can also cause tissue injury. The effect of lipid solubility on PK and, subsequently, pharmacodynamics (PD) was studied by Arendt et al, 28 who compared 3 BZDs used in treating seizure emergencies to illustrate the complex effects of lipid solubility on PD. Cats with implanted electroencephalography (EEG) electrodes were administrated IV DZP, lorazepam (LZP), or MDZ. The onset of slow wave activity, a marker of BZD activity, was correlated with lipid solubility. MDZ had the earliest onset of effect, 0.29 minutes; followed by DZP, 0.89 minutes; then LZP, 3.8 minutes. However, LZP, the least lipid soluble among the 3 drugs, had a longer residence time in the brain resulting in a longer duration of effect, 28.3 minutes. In comparison, the duration of effect for DZP and MDZ was 6-7 minutes because these drugs more rapidly redistributed to muscle and adipose tissue. Given the very large absorptive area of the BBB, the difference in onset of effect of LZP as compared to DZP and MDZ was minor, while its duration of effect was 4-fold greater than the other 2 drugs.
Differences in lipid solubility may not be critically important when BZDs are administered intravenously; however, lipid solubility plays a crucial role if administering these drugs by an alternate route. When a route with a relatively small absorptive surface is employed for rescue therapy, drugs with poor lipid solubility will have slower rates of diffusion and, thus, a slower onset of effect. A comparison of T max following IM administration of LZP, DZP, and MDZ illustrates this concept. In a PK study in healthy volunteers in which LZP was given IM, T max was 3 hours following IM injection. 29 Garnett et al 30 carried out a study in healthy subjects evaluating IM DZP and found a mean T max of 52 minutes. In contrast, Reichard et al, 31 using a similar study design, reported that the T max for IM MDZ was 30 minutes. These studies highlight the importance of lipid solubility when selecting a candidate drug for development as rescue therapy.
| ALTERNATIVES TO IV ADMINISTRATION OF RESCUE THERAPIES
Following the introduction of rectal DZP and buccal MDZ, there has been increasing effort to develop rescue therapies employing other routes of administration.
| Intrapulmonary
IP administration offers the potential for rapid onset of drug action, which makes this route desirable for rescue therapy. The therapeutic efficacy of inhaled drugs depends on the extent and site of deposition in the respiratory tract. The large surface area of alveoli in the lungs allows for efficient absorption of small molecules into the capillaries and then into the systemic circulation. 32 Often it is difficult to determine the amount of material deposited in specific regions of the respiratory tract, making dose determination issues more complex. The size, shape, and flow characteristics of aerosolized drug particles must be tightly controlled to ensure adequate deposition in the alveolar region. 33 Poorly soluble drug particles at high exposure concentrations can impair lung clearance and have been shown to result in tumor formation in rats as a nonspecific response. 34 Because of the sensitive nature of lung tissue, a US Food and Drug Administration (FDA) guidance for industry recommends thorough characterization of the drug and excipients, with additional comprehensive controls for strength, quality, and purity. 35 In addition to the physicochemical properties of the drug formulation and mechanism of the delivery device, ergonomic and physiologic constraints for specific patient populations should be considered. IP drug products designed for adult patients may not be suitable for pediatric or geriatric patients. Furthermore, the pathophysiologic changes in patients experiencing a seizure (eg, tachypnea, hypopnea, apnea, stridor, postictal cough, and neurogenic pulmonary edema) 36 could limit drug deposition.
Inhalation studies have numerous experimental variables, and thus studies must be highly standardized to enable reproducible results and meet regulatory requirements compared to other routes of administration. 37 Engage Therapeutics is developing IP alprazolam administered via their Staccato System. 38 The system utilizes a heat package with a stainless steel plate, onto which a thin film of drug is coated. A single normal inhalation activates the system, causing the plate to instantaneously heat and sublimate the drug, which then condenses into small particles that are delivered to the vascularized tissue of the deep lung. As shown in Figure 1 , following IP administration, alprazolam's T max is approximately 2 minutes. 39 However, only drugs that are thermally stable and have a high vapor pressure are suitable for thermal vaporization aerosol devices, which limits the number of compounds that can be administered by this approach. 40 Because alprazolam does not have an indication for seizures, one or more phase III clinical trials will likely be needed for FDA approval.
| Subcutaneous
Subcutaneous drug administration offers the benefits of easy access and administration. However, the volume of an SC dose should be less than 2 mL to avoid adverse events at the injection site, such as injection pain and leakage. 41 This volume limitation precludes the formulation with therapeutically relevant concentrations of many lipophilic drugs without the use of organic solvents or other solubilizing agents, which may irritate tissues and lead to induration, sloughing, or abscess formation. 26, 42 If frequent injections are necessary, the injection site should be rotated to allow time for the tissue to recover. Correctly performing a manual SC injection requires training and some psychomotor skill, so automated devices are preferred to ensure consistent delivery.
Xeris Pharmaceuticals, Inc. is developing an autoinjector SC DZP formulation. This system offers advantages including ease of use and an estimated 2-year shelf life. The company proposes that the product will have an injection volume ≤200 μL to deliver a therapeutic dose. In a rodent study, the PK profile, including T max of approximately 30 minutes, was statistically equivalent to IM DZP. 43 This product is currently in preclinical development, has orphan designation, and investigational new drug enabling studies are underway.
| Intramuscular
IM delivery shares many of the same advantages and drawbacks as SC. Among the limitations is a relatively slow rate of drug absorption compared to IP or IN routes and the risk of improper injection. A longer needle is needed is needed (1-1.5 inches) to pass through the SC adipose tissue and reach the muscle. The thickness of the adipose tissue depends on the injection site location and varies significantly within patient populations. For example, obese or emaciated patients would require different needle sizes. However, there is a lower instance of injection site reactions with IM delivery compared to SC. 44 More than 30 years ago Jawad et al 45 reported that IM MDZ compared favorably with IV DZP in terms of onset of reduction in spike wave activity in a group of patients with epilepsy. This set the stage for the subsequent development of IM MDZ for seizure emergencies using autoinjector technology. A phase I study in 39 healthy volunteers showed rapid absorption over a range of 5-30 mg doses administered using an IM autoinjector. 31 Following a 15 mg dose, the mean C max and T max were 197 ng/mL and 0.5 h, respectively. A subsequent phase III trial demonstrated that IM MDZ using an autoinjector was superior to a clinically relevant IV LZP dose for treatment of SE when both are administered by paramedics. 46 The primary outcome, absence of seizures upon arrival in the emergency department, was achieved in 73% of patients in the IM MDZ group vs 63% given IV LZP. Pfizer states that the US Departments of Defense and Health and Human Services are pursuing FDA approval for the IM autoinjector MDZ product. Should approval be granted, Pfizer plans to market this autoinjector to health care professionals. 
| Intranasal
Nasal administration is inherently attractive as it has the potential for faster drug administration and absorption, requires minimal training, is easily performed, and carries little risk of injury. Onset of effect, at least with MDZ, may be faster than other non-IV routes of administration. Rapid distribution into the central nervous system (CNS) is supported by EEG studies, for example, Hardmeier et al 48 and Scott et al. 49 Rapid distribution may also contribute to a higher frequency of CNS side effects as compared to rectal DZP, but these appear to be in line with those observed following comparable doses of IV DZP. 50 Drugs deposited in the nasal cavity are transported laterally toward the nasopharynx at a rate of 5-6 mm/min by beating cilia on the surface of the mucosa. With a transit time of 15-20 minutes, this mucociliary clearance could remove drug from the nasal cavity before the full dose is absorbed into the nasal mucosa and lead to subtherapeutic plasma concentrations. 51 Lower bioavailability can also result from larger dose volumes. The nasal cavity accommodates up to 200 μL of solution. Excess volume tends to drain into the nasopharynx or out of the anterior nares. 52 Solubilizers used to formulate BZDs at concentrations high enough to avoid drainage can irritate the mucosa and result in significant discomfort. 22 A patient's pathophysiologic state, such as sinusitis or ictal nasal secretions, could lead to variations in absorption rates and bioavailability for INdelivered drugs. Therefore, nasally administered BZDs for treatment of seizure emergencies must possess certain characteristics: (1) high and consistent absorption, (2) rapid onset of effect, and (3) minimal irritation of sensitive nasal tissues. Proximagen, Ltd. (formerly Upsher Smith Laboratories) is developing IN MDZ. In a phase I study, 53 the T max averaged 10-12 minutes at doses from 2.5-7.5 mg (Figure 2A ), whereas the absolute bioavailability ranged from 62-73%. At doses up to 7.5 mg, the onset of CNS side effects such as psychomotor impairment and sedation occurred within 15 minutes, but these measures returned to baseline values by 4 hours ( Figure 2B ). Other adverse effects included nasal discomfort (84%), throat irritation (84%), and increased lacrimation (76%). The company reports that it has completed its clinical studies and that a new drug application is in preparation.
54
Neurelis, Inc has developed a vitamin E-based formulation, which increases DZP solubility to 10 mg/100 μL. . 56 The IN formulation had a C max of 272 ng/mL, T max of 1.5 h, and 97% absolute bioavailability. In a subsequent PK study involving healthy volunteers, the T max and C max values were comparable to the same dose given rectally, but with markedly reduced variability ( Figure 4 ).
55
A group from University Hospital Basel led by Haschke developed a highly concentrated cyclodextrin-based IN MDZ. When coupled with chitosan, an absorption enhancer, the formulation attained a T max and C max of 7.2 minutes and 81 ng/mL, respectively. 57 A subsequent study evaluated the PK and PD of this formulation vs IV administration in healthy volunteers. After IN doses of 3 and 6 mg, C max (52 and 98 ng/mL) and AUC values (96 and 185 ng*h/mL) were dose proportional, and both doses displayed similar T max values (7.6 and 8.4 minutes). 48 The status of development for this formulation is unknown. Our group at the University of Minnesota is developing a novel IN drug delivery system involving a water-soluble BZD prodrug combined with a converting enzyme, which are admixed at the time of administration. As a first iteration, avizafone (AVF), a water-soluble DZP prodrug, was combined with Aspergillus oryzae protease (AOP). 58 AOP converts AVF to DZP within minutes, resulting in a supersaturated concentration of the active drug in the nasal mucosa. A pilot PK study evaluated this system in rats. As shown in Figure 5A , following IN administration of 1.6 mg/ kg, a C max of 450 ng/mL was attained at the first blood sample collection (5 minutes post-dose). The brain and plasma DZP concentrations ( Figure 5B ) at 5 minutes postdose were similar with a mean brain-to-plasma ratio of 0.88 ± (standard deviation) 0.08, suggesting very quick equilibration between blood and the central nervous system. Concentration time profiles reported in this study are comparable to those reported elsewhere using IV administration of DZP doses similar to those we used in our study, 59 indicating that the majority of the prodrug is transformed to the active drug and absorbed through the nasal mucosa. This pilot study demonstrated the feasibility of using a prodrug and converting enzyme as a novel drug delivery system for rescue therapy. The supersaturated DZP concentrations at the site of administration should result in very rapid absorption, offering the potential for earlier onset of action. Since these initial studies we have determined that human aminopeptidase B, which is already present at low levels in nasal tissues, also rapidly converts AVF to DZP.
| Other drug candidates for rescue therapies
Although BZDs are the drugs of choice for treating seizure emergencies, there is interest in evaluating other drugs such as allopregnanolone and brivaracetam as rescue therapies. The groups developing these products are investigating IM administration as the method of drug delivery (see Table 1 ).
| CONCLUSION
The number of approaches and products to treat seizure clusters and other seizure emergencies is expanding. Each approach has advantages and disadvantages in terms of ease of use, onset and duration of action, and adverse effects. Anatomic and physiologic factors and physicochemical properties are the main determinates controlling drug selection and route of administration. Table 1 summarizes the status of rescue therapies currently under development. These new approaches offer ease of use and convenience, and may lead to faster time of seizure cessation, resulting in fewer emergency department visits and improved quality of life. Advances in seizure prediction technology combined with the development of drug delivery systems that provide rapid onset of effect have the potential to prevent seizures from occurring. Such approaches could reduce or eliminate the need for chronic oral drug therapy, thereby radically altering the treatment paradigm for epilepsy.
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